Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on Five Below, Raises Price Target to $225

Keybanc Maintains Overweight on Five Below, Raises Price Target to $225

Keybanc analyst Bradley Thomas maintains Five Below (NASDAQ:FIVE) with a Overweight and raises the price target from $205 to $225.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Keybanc analyst Bradley Thomas maintains Five Below (NASDAQ:FIVE) with a Overweight and raises the price target from $205 to $225.

Deutsche Bank Maintains Hold on T. Rowe Price Gr, Raises Price Target to $123

By Benzinga Newsdesk

November 15, 10:38 AM

Deutsche Bank analyst Brian Bedell maintains T. Rowe Price Gr (NASDAQ:TROW) with a Hold and raises the price target from $97 to $123.

TROW

News

What’s Going On With AT&T Shares?

By Henry Khederian

September 25, 12:13 PM

AT&T Inc. (NYSE: T) shares are trading slightly lower by 0.5% to $15.05 during Monday's session, depsite a lack of company-specific news.

Heron Therapeutics Separates Chairman & CEO Roles; Barry Quart Departs

By Akanksha Bakshi

April 3, 10:44 AM

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced the appointment of Craig Collard as Chief Executive Officer (CEO), effective immediately. Collard succeeds Barry Quart,…

HRTX

Analyst Ratings

10 Analysts Have This to Say About Zimmer Biomet Holdings

By Benzinga Insights

March 29, 3:01 PM

Over the past 3 months, 10 analysts have published their opinion on Zimmer Biomet Holdings (NYSE:ZBH) stock. These…

ZBH

Keybanc Maintains Overweight on Five Below, Raises Price Target to $225

Related Posts

Deutsche Bank Maintains Hold on T. Rowe Price Gr, Raises Price Target to $123

What’s Going On With AT&T Shares?

Heron Therapeutics Separates Chairman & CEO Roles; Barry Quart Departs

10 Analysts Have This to Say About Zimmer Biomet Holdings